Deals > All

Ireland United Kingdom East/South/London Midlands North & Yorkshire Northern Ireland Scotland Wales

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 3057 | Ordered by Date (descending)
1 2 3 ... 29 30 31

Deal: Collaboration or Financing	Date
ReViral–OrbiMed: investment, 201509 financing round Series A totalling $21m incl new + co-lead investor Orbimed	2015-09-08
Baxalta–Novimmune: therapeutic antibodies, 201509– collab RnD €na bispecific antibodies for hemophilia A	2015-09-02
Intrexon–SEVERAL: investment, 201508 public offering $230m w 4.878k + 732k shares common stock at $41/share	2015-08-20
CXR Biosciences–Concept Life Sciences: investment, 201508 acquisition of CXR by Concept Life Sciences	2015-08-17
Oxitec–Intrexon: investment, 201508– acquisition $80m cash + $80m common stock of Oxitec Ltd by Intrexon Corp	2015-08-10
GSK–San Raffaele: gene therapy, 201505 collab existent gene therapy for rare diseases with Telethon + OSRI	2015-05-01
Blueberry Therapeutics–SEVERAL: investment, 201504 financing round $1.75m from UK + Swiss investors	2015-04-08
HiberGene–SEVERAL: investment, 201504–201704 financing round Series B €6.7m led by Cantor Fitzgerald	2015-04-01
Premaitha–Illumina: molecular diagnostics, 201809– license agreem as part of settlement incl Premaitha to developm IONA MDx test for Illumina systems	2015-03-16
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital	2015-03-04
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne	2015-03-04
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund	2015-03-04
Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures	2015-03-04
Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One	2015-03-04
Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m	2015-03-01
Synthace–SEVERAL: investment, 201502 financing round £2.2m incl SOSventures + Bioeconomy Capital et al	2015-02-11
G1 Therapeutics–SEVERAL: investment, 201502 financing round Series B $33m co-led by Eshelman Ventures + RA Capital Management	2015-02-05
HiberGene–SEVERAL: investment, 201502 financing round Series A €2m	2015-02-01
Fluidic Analytics–SEVERAL: investment, 201501 financing round Series A £1.56m ($2.4m) led by Cambridge Enterprise	2015-01-12
Boston Biotech Conference–Informa: investment, 2015 acquisition 100% £12.7m in cash net of cash acquired	2015-01-01
Morphogen-IX–Cambridge Innovation Capital: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise	2015-01-01
Morphogen-IX–Medicxi Ventures: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise	2015-01-01
Morphogen-IX–SEVERAL: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise	2015-01-01
Morphogen-IX–Univ Cambridge: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise	2015-01-01
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana	2014-12-01
Principia Biopharma–SEVERAL: investment, 201404 financing round Series B $50m led by Sofinnova Ventures	2014-04-22
Principia Biopharma–SEVERAL: investment, earlier than 201404 financing round Series A $40m	2014-04-22
Cadence Pharmaceuticals–Mallinckrodt: investment, 201402 acquisition $1.3b cash tender offer by Mallinkcrodt plc	2014-02-11
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon	2014-01-01
Optos–Nikon: investment, 2014 acquisition $400m of Optops plc by Nikon	2014-01-01
OxSyBio–SEVERAL: investment, 2014c seed financing round £1m	2014-01-01
Tusk Therapeutics–Droia Ventures: investment, 201809 existent majority shareholder + founding investor Droia Oncology Ventures	2014-01-01
Mission Therapeutics–GSK: investment, 201311 financing round Series B totalling £20m incl existing investor SR One	2013-11-18
Mission Therapeutics–Imperial Innovations: investment, 201311 financing round Series B totalling £20m incl existing investor Imperial Innovations	2013-11-18
Mission Therapeutics–Pfizer: investment, 201311 financing round Series B totalling £20m incl new investor Pfizer Venture Investments	2013-11-18
Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund	2013-11-18
Mission Therapeutics–Sofinnova: investment, 201311 financing round Series B totalling £20m incl existing investor Sofinnova Partners	2013-11-18
Synthace–SEVERAL: investment, 201309 financing round £1.3m led by Sofinnova Green Seed Fund with syndicate of angel investors	2013-09-24
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management	2013-01-01
Neuro-Bio–SEVERAL: investment, 2013 seed investment	2013-01-01
Omthera Pharmaceuticals–Sofinnova: investment, –2013 existent investor Sofinnova Partners at time of sale to AstraZeneca	2013-01-01
Pfizer–Mission Therapeutics: DUB inhibitors, 202007– collab expansion with evaluation + option agreem for DUB target validation	2013-01-01
Vivacta–Novartis: investment, 2012 acquisition by Novartis	2012-01-01
Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare	2011-03-31
Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures	2011-03-31
Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare	2011-03-31
SP Industries–Graham Partners: investment, 201103 acquisition by Graham Partners	2011-03-01
Cellnovo–LCF Rothschild: investment, 201101 investment by EdRIP	2011-01-01
Aircraft Medical–Medtronic: investment, 2010 (date ca.) aquisition $110m in cash by Medtronic	2010-01-01
Shionogi–Stallergenes: antiallergic, 2010– collab developm + registration + marketing in JP of immunotherapy tablets	2010-01-01
Sanofi–Oxford BioMedica: ophthalmic gene therapy, 2009–202006 collab developm + commerc Sanofi RIGHTS RETURNED 6/20	2009-01-01
ClinPhone–Parexel: investment, 2008 acquisition of ClinPhone by Parexel	2008-01-01
Isoprime–Elementar: investment, 2008 acquisition of Isoprime Ltd by Elementar Analysensysteme GmbH	2008-01-01
Servier–Vernalis: cancer drugs, 2007– collab fragment + structure-based drug discovery	2007-01-01
Commonwealth Holdings–MassMutual: investment, 1990 acquisition $150m of Oppenheimer Management Corp from British & Commonwealth Holdings plc	1990-01-01
Brainomix–Tencent: investment, 202112 financing round Series B totalling £16m incl new + co-investor Tencent Holdings
Brainomix–Univ Oxford: investment, 202112 financing round Series B totalling £16m incl co-investor Oxford University Innovation Fund

1 2 3 ... 29 30 31

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)